Clément Paris received his Ph.D from Strasbourg University, studying cationic oligonucleotide. In 2013 he pursued his postdoctoral studies at the University of Barcelona on the topic oligonucleotide conjugation. In 2016 he joined nLife therapeutics in Spain for working cell specific delivery of ASOs in brain. In 2018 in joined the Cancer Research Center of Marseille (CRCM) France to develop ASO nanoparticle for prostate cancer theranostic. Since 2021 Clément is an Associate Principal Scientist -Medicinal Chemistry in Early Respiratory & Immunology (R&I)| BioPharmaceuticals R&D department at AstraZeneca, Sweden.